• Daré Bioscience received a $1.5 million grant installment for preclinical development of contraceptive DARE-LARC1, bringing total non-dilutive funding to approximately $43.3 million.
• Remaining funding of approximately $5.6 million under the grant commitment of up to approximately $48.9 million depends on milestones and other requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300832PRIMZONEFULLFEED9856602) on October 30, 2026, and is solely responsible for the information contained therein.